Biotech vet Paul Bren­nan takes helm at re­gen­er­a­tive med biotech; Ax­cel­la names CFO

→ Re­gen­er­a­tive med­i­cine com­pa­ny, Nerv­Gen Phar­ma — fo­cused on the treat­ment of nerve dam­age — has tapped Paul Bren­nan to head the helm of the com­pa­ny as CEO and pres­i­dent. Bren­nan is the suc­ces­sor to Ernest Wong, who will con­tin­ue to serve as a con­sul­tant to the com­pa­ny. In ad­di­tion, the com­pa­ny has en­list­ed Lloyd Macken­zie in the new­ly cre­at­ed po­si­tion of COO. Bren­nan’s pre­vi­ous stints in­clude roles at Eu­prax­ia Phar­ma­ceu­ti­cals, Aquinox Phar­ma­ceu­ti­cals, Ar­bu­tus Bio­phar­ma (for­mer­ly Tek­mi­ra Phar­ma­ceu­ti­cals) and AnorMED among oth­ers. Bren­nan played roles in han­dling the sale of As­pre­va to Vi­for Phar­ma for $915 mil­lion, the sale of AnorMED to Gen­zyme for $580 mil­lion and the merg­er of Tek­mi­ra and On­Core Bio­phar­ma to form Ar­bu­tus Bio­phar­ma, val­ued at over $1 bil­lion on the day of the trans­ac­tion. Macken­zie hails from his re­cent role as chief de­vel­op­ment of­fi­cer at No­table Labs and pri­or to that was the COO at Aquinox Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER